Trial Profile
A Retrospective study to evaluate Peripheral Blood Biomarkers as predictors of clinical outcome associated with Nivolumab treatment in patient with advanced Non–Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Nov 2017
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 20 Nov 2017 Results published in the Journal of Thoracic Oncology
- 07 Nov 2017 New trial record
- 18 Oct 2017 Results presented at the 18th World Conference on Lung Cancer